Actinium Pharmaceuticals, Inc

Actinium Pharmaceuticals, Inc.

ATNM: NYSE AMERICAN

November 2019 Disclaimer and Safe Harbor

The information presented herein contains express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Actinium Pharmaceuticals, Inc. (“Actinium”) that are not historical facts. These forward- looking statements include statements regarding Actinium’s expectations for its product candidates (including their therapeutic and commercial potential, anticipated future development activities, anticipated timing of development activities, including initiation of clinical trials and presentations of clinical data and the indications Actinium and its collaborators plan to pursue), future results of operations and financial position, business strategy, strategic collaborations, any royalty or milestone payments and Actinium’s ability to obtain and maintain intellectual property protection for its product candidates. Such forward-looking statements may be identified by words such as “believes”, “may”, “will”, “expects”, “endeavors”, “anticipates”, “intends”, “plans”, “estimates”, “projects”, “should”, “objective” and variations of such words and similar words. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on Form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Any forward-looking statements that Actinium makes in this presentation speak only as of the date of this presentation. Except as required by law, Actinium assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date hereof. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by Actinium or any director, employee, agent, or adviser of Actinium. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. The content of this presentation is subject to copyright, which will be asserted by Actinium, and no part of this presentation may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission in writing from Actinium.

Actinium Pharmaceuticals 2 Company Highlights

Late-stage and diverse Antibody Radiation-Conjugate (ARC) pipeline maturing and generating data amidst growing interest for targeted radiotherapies

Iomab-B is a highly differentiated and potentially transformative targeted conditioning agent for bone marrow transplant (BMT)

Pivotal Phase 3 SIERRA trial for Iomab-B over 50% enrolled with promising interim results showing clear value proposition in AML despite 8 recently approved therapies

Leading late-stage pipeline focused on targeted conditioning for BMT and CAR-T leveraging our ARC capabilities and expertise

Potential best-in-class CD33 program under development in multiple indications including targeted conditioning, ARC combinations and therapies

AWE technology platform drives innovation and future opportunities including partnerships, next-generation ARC’s and solid tumor initiatives

Actinium Pharmaceuticals 3 Executive Management Team

Highly seasoned and experienced management team executing on clinical, R&D, IP & BD milestones

Sandesh Seth Mark Berger, MD Dale Ludwig, PhD Chief Executive Officer and Chief Medical Officer Chief Scientific Officer Chairman of the Board

Anil Kapur Steve O’Loughlin Chief Commercial Officer Principal Financial Officer

Actinium Pharmaceuticals 4 AWE Platform Enables Pipeline, Future Opportunities Our AWE technology platform allows us to create Antibody Radiation-Conjugates (ARC’s) for multiple areas of clinical development

AWE Technology Platform Areas of Focus

Scientific Founders Linker Isotope Targeted Conditioning

▪ Bone Marrow Transplant (BMT) Antibody ▪ CAR-T and Adoptive Cell Therapy ▪ Two Pivotal Programs

Collaborators ARC Therapeutics and Combinations

▪ Internalized targeted radiation ▪ Synergistic with chemotherapy, Strong, Growing IP Portfolio of 100+ Patents targeted agents and immunotherapy

Multiple Targets Other Near-Term Opportunities

CD45 CD33 CD38 Leukemia, Lymphoma AML, MDS MM and Solid Tumors Next-Generation ARC’s and immune cells and MM leukemia cells

Multiple Isotopes(1)

Iodine-131 Actinium-225 Lutetium-177 Range: 2.3 mm Range: .048 mm Range: 1.5 mm Energy: 0.6 MeV Energy: 5.8 MeV Energy: 0.47 MeV Actinium Pharmaceuticals 1) Pouget J.-P. et al. Nat. Rev. Clin. Oncol. 8, 720–734 (2011); published online 8 November 2011. 5 AWE Platform Powers Our Pipeline of ARC’s

Deep pipeline, including a Phase 3 asset with near-term data

Potential Development Stage Focus Program Indication Preclinical Phase 1 Phase 2 Phase 3

Iomab-B Targeted Conditioning r/r AML 55+ Pivotal Phase 3 SIERRA BMT – CD45 Iomab-B AML, MM, ALL, Phase 1/2 BMT – CD45 NHL/HL

Iomab-ACT CAR-T Programs Planned Phase 1 CAR-T – CD45 SBU Opportunity Actimab-MDS MDS Phase 1 Planned Pivotal Program BMT – CD33 Actimab-A + ARC Therapeutics and r/r AML Phase 1 Combinations Venetoclax Actimab-A r/r AML Phase 1 CLAG-M

Actimab-M Multiple Myeloma Phase 1

Ac-225- AWE Platform Multiple Myeloma Preclinical Daratumumab (CD38)

Ac-225 ARC’s Solid Tumor Preclinical

Ac-225 + Undisclosed Undisclosed Collaboration Targeting Agents

Actinium AML – Acute Myeloid Leukemia, MDS – Myelodysplastic Syndrome, MM – Multiple Myeloma, ALL – Acute Lymphoblastic Leukemia, NHL / HL – Non-Hodgkin’s / Hodgkin’s Pharmaceuticals Lymphoma 6 Why BMT and Targeted Conditioning

BMT is a potential cure for multiple diseases with significant opportunity for innovation and growth

• The bone marrow may start to produce cancerous cells, leading to diseases like leukemia, lymphoma, and other disorders

• In many instances, a BMT is the only curative treatment option for patients with these diseases

Actinium is focused on the conditioning necessary prior to Bone Marrow Transplant

01 Conditioning 02 Transplant 03 Engraftment 04 Outcomes

BMT Process

Eliminate cancer cells Infuse healthy cells Infused cells take hold and Potential for extended and the diseased bone from patient or donor rebuild patient’s blood and survival or curative marrow immune systems outcomes

Actinium Pharmaceuticals 7 The Current BMT Conditioning Dilemma

Patients have restricted access and suboptimal outcomes to potentially curative BMT

Why is patient access restricted and outcomes ARC’s like Iomab-B can solve the BMT How big is the BMT access gap? suboptimal conditioning dilemma and access gap

Today’s standard of care conditioningOnly regimens are either “too hot” or “too21,000 cold” patients Limitation:received Tooa toxic BMT, many in patients Chemotherapy - cannot2017 tolerate(2) Myeloablative Conditioning Result: Restricted access and high Treatment Related Morality

Limitation: Low-dose ARC Advantages: Can’t eliminate all disease chemo/radiation >150,000 - Delivers greater amounts of radiation to target cells - Faster time to BMT - Reduced Result: - Fewer toxicities Intensity High Relapse Rates Patients - Simultaneous tumor and marrow ablation Conditioning that could potentially benefit from a BMT - Better tolerated, stronger patient for BMT that do not receive one today

Actinium 1) Cancer Facts & figures, 2018. American Cancer Society, 2018. Leukemia, Lymphoma and Myeloma. 2) CIBMTR 2017 US Data. Transplants for AML, NHL, Hodgkin Disease and Multiple Myeloma Pharmaceuticals 8 Iomab-B Value Proposition: Enhanced Access, Improved Outcomes Transplant becomes a viable option for older patients with active, relapsed or refractory disease

Prior Clinical Experience

300+ patients 12 clinical trials 6 diseases Improved (AML, MDS, MM, survival and ALL, NHL/HL) curative outcomes AML – Current Situation vs. POC Results

Current BMT Conditioning Approaches Iomab-B BMT Conditioning(3) Salvage Chemo(1) Chemo + BMT(2)

30%

19% Observed ~10% ~10% Overall Survival ~0% ~0%

1-year 2-year 1-year 2-year 1-year 2-year

Observed Patients with active disease Time to 42 days 12 days generally do not receive BMT BMT

1) Roboz et al. J Clin Oncol 32:1919-1926 (2014) Intl Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients with Relapsed/Refractory Acute Myeloid Leukemia (N=381) Actinium 2) Armistead et al. Biol Blood Marrow Transplant 15 :1431-1438 (2009) MD Anderson outcomes analysis. (Chemo + BMT N=19) Pharmaceuticals 3) Pagel et. al. Blood 114:5444-5453 (2009) and additional data on file (N=36) 9 Ongoing Pivotal Phase 3 SIERRA Trial for Iomab-B

The only randomized Phase 3 trial investigating a BMT option for patients older than 55 years with active, relapsed or refractory AML • 150 patients total, 75 patients per arm • Primary Endpoint: Durable Complete Response (dCR) at 6 months • Secondary Endpoint: 1-year overall survival (OS) • Need to show a 2x difference in dCR to achieve primary endpoint • Additional protocol-defined safety updates at 50% and 75% of planned enrollment

Primary Secondary No CR Endpoint Iomab-B → BMT (1) Endpoint CR 6-month dCR 1-year OS 150 patients Active, R/R AML Randomized 1:1 Crossover if no Patients not achieving CR are CR failures for primary endpoint No CR Physician’s Choice(2,3) BMT CR Other Modality

1) Pagel et. al. Blood 114:5444-5453 (2009) and additional data on file (N=36) 2) Roboz et al. J Clin Oncol 32:1919-1926 (2014) International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients with Relapsed/Refractory Acute Actinium Myeloid Leukemia (N=381) Pharmaceuticals 3) Armistead et al. Biol Blood Marrow Transplant 15 :1431-1438 (2009) MD Anderson outcomes analysis. (Chemo + BMT N=19) 10 SIERRA Pivotal Phase 3 Trial: Putting 50% Findings into Context

Iomab-B Arm: Universal BMT engraftment Control Arm: High primary endpoint failure with high crossover, crossover rescue

Potential patient pool available for primary 100% engraftment for all endpoint evaluation in Iomab-B arm patients receiving therapeutic dose of Iomab-B BMT 100-day Primary Engraftment non-relapse TRM Endpoint

Iomab-B +BMT 31/31 1/31 30 (n=37) 100% 3% 20/20 2/16 Trial 100% 13% N=150 6- (Data at Crossover 20/31 Patients not achieving CR 6x month 50%) 65% are failures for primary dCR endpoint No CR: 31/38 Control Arm 82% (n=38) CR: 7/38 2/7 5 18% 29%

Low CR rate despite Potential patient pool available for primary inclusion of targeted agents endpoint evaluation in control arm

1) No therapy dose (6) due to: declining KPS (3), Infusion reaction (1), unfavorable biodistribution (1), post-randomization eligibility (1) Actinium 2) Ineligible for crossover (9) due to: hospice care/progression (4), declined/ineligible for HCT (2), died pre-crossover (3), eligible for crossover (2) did not receive Iomab-B due Pharmaceuticals to declining status 3) ANC engraftment data not available (1), platelet engraftment data not available (5) 11 High Engraftment Rate Predictive of Improved Survival

Interim results of the SIERRA trial show universal engraftment implying it is trending like the PoC trial

Standard of Care Previous Iomab-B Studies at FHCRC SIERRA Trial

Study 1809(2) SOC – No BMT(1) • Iomab-B treatment provides a significantly higher rate of engraftment 87% 100% 73% compared to chemotherapy-based BMT in several trials 100% 50% 32% • Engraftment in the proof of concept trial informing SIERRA was “near universal(3) 0% 50% r/r advanced AML and high-risk MDS: 16 – 50 y/o

10% Study 2186(2) Engraftment 1-year OS 1-year OS SOC 100% 90% 0% 100% 42% 100% 50% 17% 90% (1) 100% Chemo & BMT 80% 0% 70% 80% r/r advanced AML and high-risk MDS: 18+ 60% Iomab-B POC Study(2) 50% 60% 100% 100% 40% 40% 30% 50% 30% 20% 20% 12% 10% 10% 10% 10% 0% 0% 0% r/r advanced AML and high-risk MDS – 50+

1) Biol Blood Marrow Transplant 15 :1431-1438 (2009) MD Anderson outcomes analysis. (Salvage Chemo n = 95) (Chemo + BMT N=19). 2) Pagel et. al. Blood 114:5444-5453 (2009) (N=36) and additional Iomab-B data on file. Actinium 3) Agura et al. Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Pharmaceuticals Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial. ASH 2018 Abstract 1017. 12 Potent Single-Agent Activity of Iomab-B Rapid peripheral blast reduction and anti-leukemic effect typically associated with improved outcomes in AML patients is also observed with Iomab-B

98% reduction in peripheral blasts by day 3

SOHO 2019 100% reduction in Honorable peripheral blasts by day 8 Distinction Recipient

▪ First single agent activity of Iomab-B from the SIERRA trial(1) ▪ Rapid peripheral blast clearance with cytotoxic chemotherapy correlated with patient responses(2) and identified as an independent prognostic marker for RFS (Relapse-Free Survival) that superseded all other known risk factors (3)

1) Tomlinson et al. Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anit-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial. Poster 423. ASCO 2019 Annual Meeting. 2) Gianfaldoni et al. clearance of leukemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukemia: Actinium a pilot study. British Journal of Haematology, 2006 March 16; 134, 54-57. Pharmaceuticals 3) Elliott et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood. 2007 Dec 15; 110(13):4172-4. Epub 2007 Oct 1 13 Iomab-B Compared to Recently Approved AML Therapies

The inclusion of targeted agents, namely venetoclax, have had no impact on BMT access or CR rates for patient’s randomized to the control arm

BMT Rate Control Arm Therapies

100%

(31/31) Percentage of Patients of Percentage 27% (3/11) • 12/38 patients (32%) in the control arm received 18% (7/38)(7/38) targeted therapies • 11/12 patients (92%) received venetoclax + HMA or Iomab-B1 All Control venetoclax + LDAC Arm HMA/LDAC

Actinium 1) Patients receiving a therapeutic dose of Iomab-B Pharmaceuticals 14 Positive Trends Continue to Hold in SIERRA

Higher rates of BMT/engraftment and lower rates of TRM observed with Iomab-B vs. control arm

Potential patients for dCR evaluation

25% 50% Enrollment Enrollment

30 6x

Iomab-B Control Arm

25% 50% 25% 50% Enrollment Enrollment Enrollment Enrollment

18/181 31/311 4/18 7/38 6x BMT Access 18 (100%) (100%) (21%) (18%)

100-Day Non- 0/18 1/31 1/4 2/7 Relapse TRM (0%) (3%) (25%) (29%)

Potential Patients Eligible 18 30 3 5 for dCR 5 evaluation 3

Iomab-B Control Arm

Actinium 1) Patients receiving a therapeutic dose of Iomab-B Pharmaceuticals TRM= Transplant Related Mortality 15 SIERRA Trial Outlook and Upcoming Data Events

Strong impetus from interim results and potential for multiple readouts as trial progresses

Prominent visibility of Iomab-B data at major annual medical meetings • Single-agent activity - ASCO ’19. Interim results at ASH ‘18, TCT ’19.

Growing awareness and recognition of Iomab-B’s value proposition by medical community • Increased investigator enthusiasm, new site initiations. Improving enrollment trajectory.

Topline Data

100% Enrollment

75% Enrollment

110 patients Potential Ad Hoc DMC analysis 6 months post-enrollment Evaluated for primary endpoint of dCR(2)

50% Enrollment

Potential Ad Hoc DMC analysis 6 months post-enrollment 70 patients Evaluated for primary endpoint of dCR(2)

25% Enrollment Preliminary Safety and Feasibility Data

June 2018 July 2019 Interim Events(1)

Data Monitoring Committee (DMC) and Ad Hoc Analyses • Proceeded after 25% enrollment with no safety concerns raised; additional DMC evaluations at 50% and 75% • Discretionary request at primary endpoint for 70 and/or 110 patients; study size preserved, minimal alpha impact

Actinium 1) Interim events represent scheduled DMC analyses for safety and/or futility per the study protocol. DMC may evaluate at other time points. Pharmaceuticals 2) Ad hoc efficacy analyses may be requested at the Company’s discretion. 16 Actimab-MDS: Targeted Conditioning Franchise Expansion

Actimab-MDS is Actinium’s second pivotal program in targeted conditioning

• BMT is considered the only curative treatment option for MDS patients

• High-Risk MDS patients have dismal outcomes (Median OS of 0.8 – 1.6 years vs. 3.0 – 5.3 years for intermediate and low risk patients)(1)

• Current approaches to BMT largely similar to AML (RIC or MAC)

• Novel conditioning regimen to improve access and outcomes for BMT in MDS patients

• CD33 is expressed in a vast majority of MDS patients(2) Bone Marrow • Ac-225-Lintuzumab to eliminate MDS and myeloid lineage cells

• RIC to deplete lymphoid lineage cells Progenitor Cells

• To our knowledge, no other trial of this kind for patients with MDS RIC(3)

Ac-225 Lintuzumab

Lymphoid Lineage Cells

CD33 MDS & Myeloid Lineage Cells

Actinium 1) Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012 Pharmaceuticals 2)Jilani et al. Differences in CD33 Intensity Between Various Myeloid Neoplasms. Amer Journal for Clinical Pathology. 2002, 118:560-566 17 3) Reduced Intensity Conditioning comprised of Melphalan and Fludarabine Actimab-MDS Pivotal Program Regulatory Plan

Only trial of its kind for MDS patients to our knowledge

Actimab-MDS + Allogeneic BMT RIC Conditioning

Phase I: Dose confirming Pivotal (Actimab-MDS + Allogeneic Phase BMT)

RIC Conditioning Allogeneic BMT 7 – 18 pts. Randomized Alone 2.0 – 4.0 µCi/kg Registration Trial

1H:2020 2020 - 2021

Strong Physician Support

Highly Distinguished MDS Advisory Board

Leading Cancer Institutes as Planned Trial Sites

Actinium Pharmaceuticals 18 Iomab-ACT: Targeted Conditioning for CAR-T

Strategic expansion of our targeted conditioning ARC to address major unmet needs associated with CAR-T and adoptive cell therapy

▪ Majority of CAR-T and adoptive cell therapy programs use Fludarabine (Flu) and Cyclophosphamide (Cy) (Flu/Cy) as a preferred means of lymphodepletion ▪ Patent on use of Flu/Cy conditioning for CAR-T owned by Kite Pharma, a Gilead Company ▪ Lymphodepletion is generally considered clinically necessary: ‒ Depletes lymphocytes to create suitable environment for CAR-T cells to expand and persist ‒ May reduce the patient’s tumor burden ▪ However, intense, non-targeted lymphodepletion can lead to increased toxicity and side effects

Iomab-ACT Program Addresses Significant Unmet Needs Potential Advantages of Actinium’s Iomab-ACT Program

Single dose, outpatient Selectively targets immune cells, administration including those implicated in CRS Favorable pharmacokinetics Patient access expansion Flexibility to optimize Targeted Good safety profile lymphodepletion step Potential for improved outcomes; Targeted technology available for favorable immune environment; collaboration / licensing ▪ Durability of Responses ▪ Neurotoxicity reduced tumor burden

▪ Cytokine Release Syndrome ▪ Patient Access

Actinium Pharmaceuticals 19 Significant Support for Actinium’s Iomab-ACT Technology Growing clinical data demonstrating radiation’s ability to enhance CAR-T/ACT outcomes

CD45 homes to immune privileged lymph nodes, spleen, Actinium’s multi-modal ARC technology liver and bone marrow(5)

Iomab-ACT Observed to Selectively Target and Deplete Lymphocytes While Sparing Non-Targeted Cells(1)

Bone Marrow HSC Spleen T-reg

) 0.4

w 2.0

)

a l

Source: Actinium Pharmaceuticals, Inc. 0.3 p m 100uCi

s 1.5

6 0

0 131

1 1

x I α-CD45

( (

0.2

r 1.0

1) Lymphocytes – Iomab-ACT can 2) Regulatory T cells and myeloid- r

b m

reduce lymphocyte cytokine sinks derived suppressor cells (MDSCs) m Untreated u

u 0.1 0.5

l l

creating a receptive immune – Iomab-ACT can deplete immune l

e C (1) (2)(3) C 0.0 0.0 microenvironment suppressor cells Day 4 Day 21 Day 4 Day 21 4) Blood cancer cells – Iomab-ACT 3) Macrophages – Iomab-ACT can Spleen CD8+ T cells Spleen B-Cells

10 80

)

n e

targets CD45 found on most deplete cells that may contribute to e

l p

8 p s

s 60 /

leukemia and lymphoma tumor cells cytokine release syndrome through /

6 6

0 1

6 1 x

(4) x

(

and may effect a reduction in tumor release IL-6 and IL-1 r

r 40

e b

4 b m

burden m u

u 20

e C 0 C 0 1) Gattinoni, et al., (2005). JEM. 202:907 Day 4 Day 21 Day 4 Day 21 2) Yao, et al., (2012). Blood. 119:5866. 3) Pyzer, et al., (2016). Int. J. Cancer. 139:1915. Actinium 4) Giavridis, et al., (2018). Nat. Med. 24:731.; Norelli, et al., (2018). Nat. Med. 24:739. Pharmaceuticals 5) Company generated preclinical data and pharmacokinetic modeling results. Unpublished. 20 Iomab-ACT: Targeted Lymphodepletion Program Preclinical and clinical data strongly support advancement into clinical trials

Lymphodepletion with anti-CD45 – I-131 resulted in improved Transient Lymphodepletion Achieved with a tumor control in preclinical studies(1) Single Dose Via Outpatient Administration(2)

Tumor Volume

5000 )

3 Untreated

m 4000 OT I

(

e 131

3000 I-αCD45 + OT I

u l

o 2000

o 1000

m u

T 0 0 5 10 15 20 Days

Clinical trial protocol finalized and being discussed with potential investigators and collaborators

2H:2019 – 1H:2020 2H:2020 – Select CAR-T construct to advance Present PoC clinical into the clinic with Iomab-ACT data targeted lymphodepletion

1H:2019 2H:2019 1H:2020 1H:2020

1H:2019 – 1H:2020 – Initiate clinical trial Presented validating preclinical with Iomab-ACT and data at TCT Meetings selected CAR-T construct

Actinium 1) Ludwig et al. Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy or CAR-T. Actinium Pharmaceuticals, Inc. Pharmaceuticals TCT 2019 Poster # 270 21 2) Company generated preclinical data and pharmacokinetic modeling results. Unpublished. Targeted Conditioning: Compelling Market Opportunity

Concentrated market and growing addressable patient population that could be expanded with targeted conditioning

Major markets (US, EU, Japan) can be Over 70,000 transplant procedures Targeted conditioning can enable served effectively and efficiently with lean performed in the US(1), EU(2) and Japan(3) significant expansion of the addressable infrastructure in 2016 patient population(4)

50,000 Allogeneic

40,000 Autologous

30,000

20,000

10,000

0 Japan US Europe

Distinct Opportunity For Comprehensive Portfolio Build-out Over The Next 5 years

Multiple Non- AML MDS ALL MCL MF MM FL Hodgkin's Malignant Tumors Disorders

Auto and Allogeneic Allogenic Transplants Autologous Transplants Allo / Auto Transplants

CAR-T / ACT ALL, MM, FL, DLBCL, Solid Tumors, Genetic Disorders, Rare Diseases

1) Current Uses and Outcomes of Hematopoietic Cell Transplantation 2017 Summary Slides. Center for International Blood & Marrow Transplant Research Actinium 2) European Society for Blood and Marrow Transplantation. 2017 Annual Report Pharmaceuticals 3) Activities and Outcomes of Hematopoietic Cell Transplantation in Japan 2017. The Japanese Data Center for Hematopoietic Cell Transplantation. 4) Goldman Sachs Transplant Market Analysis, 2018. 22 Highly Differentiated CD33-Alpha Program

ARC approach is driving therapeutic combinations and novel trials in indications with unmet needs

▪ Clinical experience in 100+ patients in 4 clinical trials with CD33 – Alpha ARC

▪ Phase 2 trial in r/r AML demonstrated single-agent activity inline with recently approved drugs in AML (Actimab-A: 22% vs. venetoclax: 19%(1)

▪ Radiation is a validated approach that is synergistic with other modalities

▪ Multiple opportunities to use Actimab-A in combination with chemotherapy, targeted agents and immunotherapy

CD33+ Targeted Combination/ Diseases Conditioning Therapeutic

High Dose Myelodysplastic Syndrome Targeted Conditioning

225Ac- Tailored Ac-225 dose for desired application Acute Myeloid lintuzumab Leukemia Combination Cornerstone

Multiple Low Dose Myeloma

CD33+ Cell

Actinium 1) Konopleva et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 Pharmaceuticals Oct;6(10):1106-1117. 23 Promising Interim Results: Actimab-A + CLAG-M Combo

Favorably high response rates vs approved agents from Actimab-A + CLAG-M combo in r/r AML

Overall Response Rates of Selected Therapeutic Agents for r/r AML 100%

90% 83% 80% 68% 70% 64% 60% 54% Approved Agents 50% 40% 40% 30% 19% 20% 17% 10% 0% Azacytidine Venetoclax Enasidenib Venetoclax + Gilteritinib CLAG-M(6) Actimab-A + (HMA)(1) (BCL-2)(2) (IDH2)(3) HMA(4) (Flt3)(5) CLAG-M(7) ▪ CLAG-M is the preferred salvage regimen for R/R AML patients at the Medical College of Wisconsin based on favorable institutional outcomes

▪ 83% remission rate with Actimab-A CLAG-M combination compares favorably to 54% remission rate with CLAG-M alone

▪ 50% of responding patients (3/6) achieved a Complete Remission (CR)

▪ 33% of all patients (3/9) in the trial subsequently received a BMT

▪ Combining lower doses of Actimab-A with CLAG-M appears to have a clinically acceptable safety profile

▪ All patients completed the planned cycle of Actimab-A and CLAG-M and no mortalities were observed on study

1) Itzykson et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015 Feb;39(2):124-30. 2) Konopleva et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 Oct;6(10):1106-1117. 3) Stein et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. 4) Aldoss et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018 Sep;103(9):e404-e407. Actinium 5) Perl et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728-1740. Pharmaceuticals 6) Mushtaq et al. Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. ASH Annual Meeting 2018 7) Abedin et al. Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase 1 Study. ASH 2019 Abstract #2605 24 Actimab-A + Venetoclax Combination Trial R&D team identified MCL-1 depletion with CD33-Alpha as a synergistic mechanism with Bcl-2 inhibitor venetoclax and generated strong proof of concept data that resulted in a novel combination trial

▪ Venetoclax is a Bcl-2 inhibitor approved in 3 hematologic indications 1:

▪ Single agent responses with venetoclax in r/r AML patients was 5: AML cell death reported to be 19% (CR+CRi)(1) 2:

▪ Venetoclax is approved in combination with HMAs and LDAC for patient with AML age 75+ who are unfit for standard induction therapy 4: 3: ▪ Actinium is evaluating the combination of Actimab-A and venetoclax based on a synergistic mechanism of action that is supported by promising preclinical data

▪ A Phase 1 clinical trial led by Dr. Gary Schiller of UCLA Medical Center will evaluate this novel combination

Validated Synergy(2) Improved Tumor Control(2) Improved Survival(2) 500 Vehicle

Lintuzumab )

3 400 200 nCi 225Ac-Lintuzumab

m m

( Venetoclax

300

e z

i 200 nCi 225Ac-Lintuzumab +

r Venetoclax

u 200

m u

T 100

0 0 10 20 30 40 Days Post-treatment

1) Konopleva et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 Actinium Oct;6(10):1106-1117. 2) Garg et al. 225-Ac-CD33 radioimmunotherapy potently increases the sensitivity of resistant acute myeloid leukemia lines to the Bcl-2 inhibitor venetoclax by mediating a reduction in Pharmaceuticals cellular Mcl-1 levels. Poster 3808. AACR Annual Meeting 2019. 25 Next-generation Empowered Antibodies via AWE Platform

Differentiated capabilities of ARCs ideal for multiple areas of development

♦ Significant investment in R&D and AWE platform since 2018

♦ World leader in Ac-225 R&D with comprehensive IP portfolio

Next-Gen ARCs Solid Tumors Collaborations

Ac-225 labeled CD38 demonstrated Robust activity and survival benefit with Ac- Labeling select Astellas better tumor control than naked CD38(1) 225 labeled Her2 in breast cancer model(2) targeting agents utilizing our AWE technology, Ac-225 expertise and know how

Development ARC Capabilities Critical IP Capabilities 100+ Patents, DOTA – “gold standard” Multiple Isotopes Multiple Targets Expertise and know-how in preclinical linker, Ac-225 production and development, regulatory, CMC & Actinium-225 CD45 chelation, Next-Gen Ac-225 labeling supply chain together with extensive methods Iodine-131 CD33 clinical ARC experience and commercial knowledge Lutetium-177 CD38 Actinium 1) Dawicki et al. 225Ac-CD38 Antibody Targeting is Effective and Well Tolerated in Experimental Models of Lymphoma and Multiple Myeloma. Poster 1410. 2109 SNMMI. Pharmaceuticals 26 2) Song et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.Cancer Res. 2009 Dec 1;69(23):8941-8. Expected Value Creating Milestones

Multiple value drivers from clinical assets and platform in 2019, 2020 and beyond

Milestones Status Targeted Conditioning & Lymphodepletion Present data from first 25% of patients at ASH, TCT and ASCO Reach 50% Enrollment Iomab-B Phase 3 Present additional SIERRA data 2H:2019-2020 SIERRA Trial Complete Enrollment/Topline Data 2020-2021 File BLA/Commercial Launch 2021 Present supportive preclinical data at TCT and SNMMI Iomab-ACT Secure development partner 2H:2019-2020 Clinical and strategic updates 2020

Actimab-MDS Pivotal Initiate Phase 1 clinical trial 1H:2020 Program Generate Proof of Concept Data, Initiate Pivotal Program 2020-2021

CD33 ARC Therapeutics and Combinations and AWE Present supportive preclinical data at AACR Actimab-A Venetoclax Proof of Concept Data from Actimab-A Venetoclax combination trial 2020 Complete second dosing cohort/report interim results Actimab-A CLAG-M Initiate 3rd dosing cohort 1H:2020 AWE Technology Platform Progress collaborative research partnership with Astellas

Actinium Pharmaceuticals 27 Actinium Pharmaceuticals, Inc.

Thank You ATNM: NYSE AMERICAN